Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Holdings Increased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 51.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 25,059 shares of the company's stock after acquiring an additional 8,521 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.05% of Mirum Pharmaceuticals worth $1,036,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of MIRM. Jones Financial Companies Lllp increased its stake in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares during the period. R Squared Ltd acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $69,000. AlphaQuest LLC increased its holdings in shares of Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Mirum Pharmaceuticals by 8.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after buying an additional 312 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $189,000.

Insiders Place Their Bets

In related news, CEO Christopher Peetz sold 27,279 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the transaction, the chief executive officer now directly owns 138,641 shares of the company's stock, valued at $6,129,318.61. This represents a 16.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Patrick J. Heron acquired 1,335 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the transaction, the director now owns 163,643 shares of the company's stock, valued at $7,457,211.51. This represents a 0.82% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 92,764 shares of company stock worth $4,109,161 over the last quarter. 14.36% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM traded down $0.38 during midday trading on Monday, reaching $44.63. 68,811 shares of the company were exchanged, compared to its average volume of 523,015. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a one year low of $23.83 and a one year high of $54.23. The stock's 50-day moving average price is $42.96 and its 200-day moving average price is $44.51. The stock has a market cap of $2.21 billion, a P/E ratio of -22.02 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. During the same period in the previous year, the company posted ($0.54) earnings per share. The business's revenue was up 61.2% on a year-over-year basis. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MIRM. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. JMP Securities upped their price target on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday. Finally, Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $60.73.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.